Cardinal Health 2009 Annual Report Download - page 50

Download and view the complete annual report

Please find page 50 of the 2009 Cardinal Health annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 154

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112
  • 113
  • 114
  • 115
  • 116
  • 117
  • 118
  • 119
  • 120
  • 121
  • 122
  • 123
  • 124
  • 125
  • 126
  • 127
  • 128
  • 129
  • 130
  • 131
  • 132
  • 133
  • 134
  • 135
  • 136
  • 137
  • 138
  • 139
  • 140
  • 141
  • 142
  • 143
  • 144
  • 145
  • 146
  • 147
  • 148
  • 149
  • 150
  • 151
  • 152
  • 153
  • 154

Item 6: Selected Financial Data
The consolidated financial data include all business combinations as of the date of acquisition that occurred
during these periods. The following selected consolidated financial data should be read in conjunction with the
Company’s consolidated financial statements and related notes and “Item 7—Management’s Discussion and
Analysis of Financial Condition and Results of Operations.”
CARDINAL HEALTH, INC. AND SUBSIDIARIES
SELECTED CONSOLIDATED FINANCIAL DATA
At or for the Fiscal Year Ended June 30, (1)
2009 2008 2007 2006 (2) 2005
(In millions, except per common share amounts)
Earnings Data:
Revenue .................................. $99,512.4 $90,975.5 $86,755.0 $79,573.5 $72,579.1
Earnings from continuing operations ........... $ 1,142.8 $ 1,296.0 $ 820.7 $ 1,145.3 $ 1,049.0
Earnings / (loss) from discontinued
operations (3) ............................ 8.8 4.6 1,110.4 (145.2) 1.7
Net earnings ............................... $ 1,151.6 $ 1,300.6 $ 1,931.1 $ 1,000.1 $ 1,050.7
Basic earnings / (loss) per Common Share
Continuing operations ................... $ 3.20 $ 3.62 $ 2.08 $ 2.72 $ 2.44
Discontinued operations (3) .............. 0.02 0.01 2.81 (0.34) —
Net basic earnings per Common Share .......... $ 3.22 $ 3.63 $ 4.89 $ 2.38 $ 2.44
Diluted earnings / (loss) per Common Share
Continuing operations ................... $ 3.16 $ 3.56 $ 2.03 $ 2.67 $ 2.41
Discontinued operations (3) .............. 0.02 0.01 2.74 (0.34) —
Net diluted earnings per Common Share ........ $ 3.18 $ 3.57 $ 4.77 $ 2.33 $ 2.41
Cash dividends declared per Common Share ..... $ 0.595 $ 0.500 $ 0.390 $ 0.270 $ 0.150
Balance Sheet Data:
Total assets ............................... $25,118.8 $23,448.2 $23,153.8 $23,433.3 $21,886.6
Long-term obligations, less current portion and
other short-term borrowings ................ 3,280.0 3,687.4 3,457.3 2,588.6 2,302.1
Shareholders’ equity (4) ..................... 8,724.7 7,747.5 7,376.9 8,490.7 8,593.0
(1) Amounts reflect business combinations and the impact of special items in all periods presented. See Note 3
of “Notes to Consolidated Financial Statements” for a further discussion of special items affecting fiscal
2009, 2008 and 2007. Fiscal 2006 and 2005 amounts reflect the impact of special items of $79.8 million and
$137.9 million, respectively, related to restructuring charges, acquisition integration charges and litigation
and other.
(2) During the first quarter of fiscal 2006, the Company adopted Statement of Financial Accounting Standards
(“SFAS”) No. 123(R), “Share-Based Payment,” applying the modified prospective method. Prior to the
adoption of SFAS No. 123(R), the Company accounted for equity-based awards under the intrinsic value
method, which followed the recognition and measurement principles of Accounting Principles Board
(“APB”) Opinion No. 25, “Accounting for Stock Issued to Employees,” and related Interpretations, and
equity-based compensation was included as pro forma disclosure within the notes to the financial
statements. See Note 18 of “Notes to Consolidated Financial Statements” for additional information.
(3) During the fourth quarter of fiscal 2009, the Company committed to plans to sell its United Kingdom-based
Martindale injectable manufacturing business within its Healthcare Supply Chain Services segment, and met
the criteria for classification of this business as a discontinued operations in accordance with SFAS No. 144,
“Accounting for the Impairment or Disposal of Long-Lived Assets” and Emerging Issues Task Force
28